IN2014MN01724A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01724A IN2014MN01724A IN1724MUN2014A IN2014MN01724A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A IN 1724MUN2014 A IN1724MUN2014 A IN 1724MUN2014A IN 2014MN01724 A IN2014MN01724 A IN 2014MN01724A
- Authority
- IN
- India
- Prior art keywords
- immune cell
- moiety
- further moiety
- molecule
- unwanted cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1203442.7A GB201203442D0 (en) | 2012-02-28 | 2012-02-28 | Immunotherapeutic molecules and uses |
PCT/GB2013/050499 WO2013128194A1 (fr) | 2012-02-28 | 2013-02-28 | Molécules immunothérapeutiques et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01724A true IN2014MN01724A (fr) | 2015-05-29 |
Family
ID=45991852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1724MUN2014 IN2014MN01724A (fr) | 2012-02-28 | 2013-02-28 |
Country Status (9)
Country | Link |
---|---|
US (3) | US9822180B2 (fr) |
EP (1) | EP2819701B2 (fr) |
JP (1) | JP6273215B2 (fr) |
CN (1) | CN104321081A (fr) |
AU (1) | AU2013227477B2 (fr) |
CA (1) | CA2865482A1 (fr) |
GB (1) | GB201203442D0 (fr) |
IN (1) | IN2014MN01724A (fr) |
WO (1) | WO2013128194A1 (fr) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2686020T3 (en) | 2011-03-17 | 2017-05-01 | Univ Birmingham | REDIRECTED IMMUNTERY |
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
EP3677310A1 (fr) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
SG11201509595PA (en) | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
EP4067383A1 (fr) * | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Anticorps multispécifiques, anticorps activables multispécifiques et leurs procédés d'utilisation |
BR122021025087B1 (pt) | 2013-12-17 | 2023-04-04 | Genentech, Inc | Anticorpo anti-cd3, célula hospedeira procariótica, método de produção do anticorpo biespecífico, imunoconjugado, composição, uso do anticorpo biespecífico e kit |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
EP3164417A1 (fr) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Diabodies hétérodimères bispécifiques et leurs utilisations |
CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
JP2018508481A (ja) * | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のt細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN107709363A (zh) * | 2015-05-01 | 2018-02-16 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
EP3296395B1 (fr) * | 2015-05-13 | 2021-06-30 | Chugai Seiyaku Kabushiki Kaisha | Molécule de fusion possédant la capacité à se lier à plusieurs antigènes, composition pharmaceutique, méthode d'identification d'épitopes linéaires, et méthode de préparation de la molécule de fusion possédant la capacité à se lier à plusieurs antigènes |
EP3297672B1 (fr) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Protéines trispécifiques de liaison et méthodes d'utilisation |
EP3916018A1 (fr) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anticorps anti-cd3 et procédés d'utilisation |
EP3341009A4 (fr) | 2015-08-28 | 2019-05-01 | Amunix Pharmaceuticals, Inc. | Ensemble de polypeptides chimériques et procédés de préparation et d'utilisation de ceux-ci |
CA2999138C (fr) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Polypeptides de liaison a cd3 |
KR20180081532A (ko) | 2015-10-30 | 2018-07-16 | 알레타 바이오쎄라퓨틱스, 인크. | 암 치료용 조성물 및 방법 |
AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
WO2017087789A1 (fr) | 2015-11-19 | 2017-05-26 | Revitope Limited | Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables |
CN108601819B (zh) | 2015-12-17 | 2022-03-15 | 约翰霍普金斯大学 | 用死亡受体激动剂改善***性硬化症 |
US11225520B2 (en) | 2016-02-16 | 2022-01-18 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
TW201808990A (zh) * | 2016-03-08 | 2018-03-16 | 馬弗瑞克療法公司 | 可誘導性結合蛋白和使用方法 |
EP3433280B1 (fr) * | 2016-03-22 | 2023-04-19 | F. Hoffmann-La Roche AG | Molécules bispécifiques de cellules t activées par une protéase |
KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
RU2756236C2 (ru) * | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
AU2017361081A1 (en) | 2016-11-15 | 2019-05-23 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
EP3544997A4 (fr) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | Protéine de liaison à l'antigène membranaire spécifique de la prostate |
CA3041279A1 (fr) * | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Domaine de liaison a l'antigene et polypeptide comprenant une section de transport |
CN110214151A (zh) | 2016-11-28 | 2019-09-06 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
US11230610B2 (en) * | 2016-12-09 | 2022-01-25 | Seagen Inc. | Bivalent antibodies masked by coiled coils |
KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
MA47613A (fr) * | 2017-02-22 | 2020-01-01 | Aleta Biotherapeutics Inc | Compositions et procédés de traitement du cancer |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
MY200973A (en) * | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
WO2018204717A1 (fr) * | 2017-05-03 | 2018-11-08 | Harpoon Therapeutics, Inc. | Compositions et méthodes pour thérapies par cellules adoptives |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
EP3621648A4 (fr) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | Protéines trispécifiques ciblant la msln et procédés d'utilisation |
JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗pdl1抗体、およびその使用方法 |
BR112020004543A2 (pt) | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
KR20200064096A (ko) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법 |
TW202348632A (zh) | 2017-11-28 | 2023-12-16 | 日商中外製藥股份有限公司 | 含有抗原結合域及運輸部分之多胜肽 |
US20210206845A1 (en) | 2017-11-28 | 2021-07-08 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand-binding activity |
US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
US11891426B2 (en) | 2017-12-15 | 2024-02-06 | Aleta Biotherapeutics Inc. | CD19 variants |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
BR112020016169A2 (pt) | 2018-02-08 | 2020-12-15 | Genentech, Inc. | Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit |
US20210260163A1 (en) * | 2018-03-09 | 2021-08-26 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
CN112437672A (zh) * | 2018-05-07 | 2021-03-02 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
EP3816182A4 (fr) * | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à un ligand contenant un anticorps à domaine unique |
WO2019230866A1 (fr) * | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprenant un domaine de liaison de il-1r1 et une fraction de transport |
WO2020010104A1 (fr) * | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Complexes ensemble d'anticorps ciblant une tumeur |
EP3833385A4 (fr) * | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
JP2022513888A (ja) * | 2018-12-14 | 2022-02-09 | プロヴィヴァ セラピューティクス (ホン コン) リミテッド | Il-15組成物およびその使用方法 |
EP3934762A1 (fr) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Protéines de liaison à activation conditionnelle limitée |
EP3725370A1 (fr) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative |
BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
EP4023230A4 (fr) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à un site de clivage d'anticorps |
WO2021119505A1 (fr) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anticorps anti-ly6g6d et méthodes d'utilisation |
JP7483896B2 (ja) * | 2020-01-17 | 2024-05-15 | エショー バイオセラピー, インク. | オフターゲット毒性を低下させるプロ抗体 |
EP4090686A4 (fr) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc | Pro-anticorps réduisant la toxicité hors cible |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
KR20220166814A (ko) | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
EP4146695A1 (fr) | 2020-05-04 | 2023-03-15 | Immunorizon Ltd. | Constructions d'anticorps tri-spécifiques précurseurs et leurs procédés d'utilisation |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CR20220604A (es) | 2020-06-19 | 2023-01-23 | Hoffmann La Roche | Anticuerpos biespecíficos para linfocitos t activados por proteasa |
EP4172203A1 (fr) | 2020-06-25 | 2023-05-03 | F. Hoffmann-La Roche AG | Molécules bispécifiques de liaison à l'antigène anti-cd3/anti-cd28 |
US20230321239A1 (en) | 2020-08-14 | 2023-10-12 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor t cells for treating autoimmunity |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
JP2023552812A (ja) | 2020-12-09 | 2023-12-19 | ジャナックス セラピューティクス,インク. | Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法 |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
WO2022170619A1 (fr) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anticorps anti-cd3 et leurs méthodes d'utilisation |
AU2022310081A1 (en) * | 2021-07-13 | 2024-02-01 | Sinomab Bioscience Limited | Methods of treating neurological diseases |
WO2023186760A1 (fr) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques améliorés dirigés contre des lymphocytes t pouvant être activés par une protéase folr1 |
WO2023196818A1 (fr) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Compositions et procédés de complémentation génétique |
WO2023201291A1 (fr) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Compositions pharmaceutiques de mosunétuzumab et procédés d'utilisation |
WO2024068572A1 (fr) | 2022-09-28 | 2024-04-04 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques améliorés de lymphocytes t activables par une protéase |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3578568A (en) | 1968-11-29 | 1971-05-11 | Atlantic Richfield Co | Purification of low molecular weight epoxides by extractive distillation with a glycol or glycol ether |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0659438A1 (fr) | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugués d'un antigène peptidique pour cellules-T et d'un groupé liant aux cellules, et leur utilisation en thérapie |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
DE69636015T2 (de) | 1995-05-03 | 2007-01-04 | Bioenhancementsments Ltd. | Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird |
US20040197336A1 (en) | 1995-05-03 | 2004-10-07 | Self Colin Henry | Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety |
JP2000503003A (ja) | 1995-12-22 | 2000-03-14 | イムノメディクス,インコーポレイテッド | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用 |
CA2265476A1 (fr) | 1996-09-12 | 1998-03-19 | Merck & Co., Inc. | Conjugues utiles dans le traitement du cancer de la prostate |
HRP970566A2 (en) | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
AU740904B2 (en) | 1997-03-20 | 2001-11-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
AU740597B2 (en) | 1997-07-10 | 2001-11-08 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 특이 폴리펩티드 및 그의 용도 |
AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
WO2000058362A1 (fr) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Nouvelles proteines capables de liaison avec la neutrokine alpha et procedes bases sur lesdites proteines |
WO2002044197A2 (fr) | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Peptides de fixation des recepteurs des cytokines |
EP1448584B1 (fr) | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Anticorps anti-cd22 mutes a forte affinite pour les cellules leucemiques exprimant des cd22 |
NZ533226A (en) | 2001-11-30 | 2006-05-26 | Crucell Holland B | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
CA2476166C (fr) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
JP5354835B2 (ja) | 2002-11-07 | 2013-11-27 | イミュノジェン・インコーポレーテッド | 抗cd33抗体、及びそれを用いた急性骨髄性白血病の治療方法 |
EP1590372A2 (fr) | 2003-02-06 | 2005-11-02 | Micromet AG | Reponse de lymphocyte t durable |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
ATE493441T1 (de) * | 2003-10-16 | 2011-01-15 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
ATE459374T1 (de) | 2003-11-28 | 2010-03-15 | Micromet Ag | Polypeptide enthaltende zusammensetzungen |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
US20060045881A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
AR050642A1 (es) | 2004-09-10 | 2006-11-08 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina |
EP1848462B1 (fr) | 2005-02-16 | 2011-10-26 | University of Zürich | Traitement du cancer à l'aide d'une immunotoxine comprenant une exotoxine a dont le site de clivage par la furine est remplacé par un site de protéase associée au cancer qui est clivé par mmp-2 ou mmp-9 |
EP1948802A4 (fr) | 2005-10-13 | 2009-01-14 | Virexx Medical Corp | Antigène chimère contenant un polypeptide du virus de l'hépatite c et un fragment fc destiné à provoquer une réponse immunitaire |
WO2007057922A1 (fr) | 2005-11-18 | 2007-05-24 | Dabur Pharma Limited | Proteines hybrides ciblees destinees a la cancerotherapie |
GB0605702D0 (en) | 2006-03-21 | 2006-05-03 | Biotransformations Ltd | Materials and methods for immune cell stimulation |
WO2008019366A2 (fr) | 2006-08-07 | 2008-02-14 | Ludwig Institute For Cancer Research | Procédés et compositions permettant un amorçage accru des cellules t par présentation croisée d'antigènes exogènes |
CA2668017A1 (fr) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Conjugues ameliores |
WO2008063113A1 (fr) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Peptides de pénétration cellulaire et construction les contenant constitués de 15 à 25 acides aminés de la protéine de suppression tumorale p14arf ou p19arf |
EP2423222B2 (fr) | 2007-01-30 | 2020-07-29 | Epivax, Inc. | Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci |
WO2008097866A2 (fr) | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Vaccins à base d'antigène cible au dcir exprimé dans des cellules présentant un antigène |
ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
GB0716160D0 (en) * | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
CA3128656A1 (fr) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Polypeptides de liaison activables et procedes d'identification et utilisation de ceux-ci |
CA2738566C (fr) | 2008-10-01 | 2024-04-30 | Micromet Ag | Anticorps monocatenaires bispecifiques specifiques d'antigenes cibles de masse moleculaire elevee |
US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
EP2356131A4 (fr) * | 2008-12-08 | 2012-09-12 | Tegopharm Corp | Ligands de masquage pour inhibition réversible de composés polyvalents |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
MX2011009439A (es) | 2009-03-10 | 2013-06-18 | Baylor Res Inst | Vacunas con especificidad de objetivo hacia celula presentadora de antigeno. |
EP2496256A4 (fr) | 2009-11-05 | 2013-07-17 | Ct Molecular Med & Immunology | Immunoconjugués comprenant des peptides issus de poxvirus et des anticorps dirigés contre des cellules présentatrices d'un antigène pour des vaccins contre les poxvirus à base de sous-unité |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
DK2686020T3 (en) | 2011-03-17 | 2017-05-01 | Univ Birmingham | REDIRECTED IMMUNTERY |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
JP2015516376A (ja) | 2012-03-19 | 2015-06-11 | ドイチェス クレブスフォルシュンクスツェントルム | T細胞エピトープを含む、b細胞受容体複合体結合タンパク質 |
WO2013163631A2 (fr) | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Anticorps activables liant le récepteur du facteur de croissance épidermique et leurs procédés d'utilisation |
US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
PE20150643A1 (es) | 2012-06-22 | 2015-05-29 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos |
WO2014052462A2 (fr) | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Anticorps activables qui se lient au récepteur d'interleukine-6 et procédés d'utilisation de ces derniers |
RU2015132436A (ru) | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
AR095502A1 (es) | 2013-03-15 | 2015-10-21 | Bayer Healthcare Llc | Anticuerpos profármaco contra el inhibidor de la vía del factor tisular |
CA2913732A1 (fr) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions et procedes permettant de conjuguer des anticorps activables |
EP4067383A1 (fr) | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Anticorps multispécifiques, anticorps activables multispécifiques et leurs procédés d'utilisation |
KR20230011497A (ko) | 2013-09-25 | 2023-01-20 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
CN114106099B (zh) | 2014-01-31 | 2024-05-24 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
-
2012
- 2012-02-28 GB GBGB1203442.7A patent/GB201203442D0/en not_active Ceased
-
2013
- 2013-02-28 CN CN201380022143.6A patent/CN104321081A/zh active Pending
- 2013-02-28 AU AU2013227477A patent/AU2013227477B2/en active Active
- 2013-02-28 CA CA2865482A patent/CA2865482A1/fr not_active Abandoned
- 2013-02-28 US US14/381,405 patent/US9822180B2/en active Active
- 2013-02-28 IN IN1724MUN2014 patent/IN2014MN01724A/en unknown
- 2013-02-28 EP EP13719592.1A patent/EP2819701B2/fr active Active
- 2013-02-28 JP JP2014559294A patent/JP6273215B2/ja active Active
- 2013-02-28 WO PCT/GB2013/050499 patent/WO2013128194A1/fr active Application Filing
-
2015
- 2015-10-21 US US14/918,807 patent/US9650445B2/en active Active
-
2017
- 2017-09-19 US US15/708,419 patent/US10106621B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160039942A1 (en) | 2016-02-11 |
US20180105599A1 (en) | 2018-04-19 |
CA2865482A1 (fr) | 2013-09-06 |
AU2013227477A1 (en) | 2014-09-18 |
US10106621B2 (en) | 2018-10-23 |
US20150183875A1 (en) | 2015-07-02 |
CN104321081A (zh) | 2015-01-28 |
GB201203442D0 (en) | 2012-04-11 |
EP2819701B2 (fr) | 2021-06-02 |
US9650445B2 (en) | 2017-05-16 |
WO2013128194A1 (fr) | 2013-09-06 |
US9822180B2 (en) | 2017-11-21 |
JP2015509952A (ja) | 2015-04-02 |
JP6273215B2 (ja) | 2018-01-31 |
AU2013227477B2 (en) | 2017-03-23 |
EP2819701A1 (fr) | 2015-01-07 |
EP2819701B1 (fr) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01724A (fr) | ||
MY185016A (en) | Progenitor cells of mesodermal lineage | |
IN2015DN00143A (fr) | ||
AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
AU348732S (en) | Carburetor main body | |
AU334338S (en) | Electronic housing portion | |
AU341122S (en) | Intake manifold | |
IN2015DN03795A (fr) | ||
AU334280S (en) | Electronic housing portion | |
IN2014DN06104A (fr) | ||
AU334339S (en) | Electronic housing portion | |
TWD163155S (zh) | 耳機 | |
AU339157S (en) | Carburettor | |
AU341133S (en) | Carburetor main body | |
IN2015DN00636A (fr) | ||
IN2014DN08721A (fr) | ||
PH12015501083B1 (en) | Novel pyridine derivatives | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
TW201611843A (en) | Methods of treatment with arginine deiminase | |
MY168166A (en) | Polymer and Composition Including Same, and Adhesive Composition | |
AU342351S (en) | Automobile | |
NZ627480A (en) | Inhibitors of iap | |
IN2014KN02745A (fr) | ||
UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
PH12015500262A1 (en) | Novel pyridine derivatives |